# High-throughput Pharmacokinetics for Drug Discovery

Robert D. Clark, Pankaj R. Daga and Robert Fraczkiewicz Simulations Plus, Inc. Lancaster CA, USA




©Simulations Plus, Inc., 2018 All rights reserved

# Many Key Properties Can be Estimated Individually in silico

- Acid/base dissociation constants (pK<sub>a</sub>'s) & ionization
- Solubility and tendency to supersaturate
- Lipophilicity
- Intestinal permeability
  - quantitative: passive permeability & local models
  - qualitative: susceptibility to active uptake or efflux on transporters
- Metabolism
  - quantitative: cytochrome P450 (CYP) clearance & local models
  - qualitative: glucuronidation & glutathione conjugation
- Binding to plasma proteins, to red blood cells & within tissues


> It takes Physiologically-Based Pharmacokinetic (PBPK) simulation to bind them all.





© 2010, The Middle-Earth Encyclopedia


# **HTPK Simulation Is Relatively Simple...**



"A thing should be made as simple as possible, but no simpler." - Albert Einstein



#### ...But Complicated Enough to Get the Job Done




<u>C</u>lose


else other than liver and kidney into a single central compartment.

# **Does HTPK Give Good Enough Answers?**

Human %Fa for 115 compounds (Zhao et al. *J. Pharm. Sci.*, **2001**, 90: 749 and elsewhere)




90% predicted within 2-fold of the reported value. 83% predicted within 1.5-fold. Human %Fb for 62 CYP-metabolized compounds (Toshimoto et al. *Drug Metab. Dispos.* **2014**, 42:1811 etc.)



81% predicted within 2-fold of the reported value.68% predicted within 1.5-fold

### Let's Avoid the Streetlight Effect...



Big data's 'streetlight effect': where and how we look affects what we see. https://theconversation.com/big-datas-streetlight-effect-where-and-how-we-look-affects-what-we-see-58122

# **Rat Bioavailability: Data Set 1**

- Data taken from a survey of all bioavailability enhancement studies published in the Journal of Medicinal Chemistry between September 2001 and September 2002
  - rat bioavailabilities for 89 compounds with 20 different targets
  - 1-12 examples from 40 papers

Current Topics in Medicinal Chemistry 2003, 3, 1269-1288

#### Molecular Design and Bioavailability


#### Robert D. Clark\* and Philippa R.N. Wolohan

#### Tripos, Inc., 1699 S. Hanley Road, St. Louis MO 63144 USA

Abstract: A "snapshot" of current medicinal chemistry work on bioavailability is drawn from issues of *J. Med. Chem.* covering the time period between September 2001 and September 2002. An exhaustive compilation of reported absolute oral bioavailability (F) values for this period is included, covering 34 structural series and 107 distinct compounds, with data for multiple species in many cases. This is supplemented with a discussion of more qualitative oral bioavailability results, and with illustrative examples addressing clearance, prodrug design, and blood/brain barrier penetration problems. Papers discussing predictions pertaining to one or another aspect of bioavailability are also discussed, and some thoughts on future directions of work on *in silico* prediction in this area are presented.





1269





#### **Experimental Fb vs.** *in silico* **Predictions of Fa and Fb**







- Albert Einstein

SCIENCE + SOFTWARE = SUCCESS

#### Why Are Some Bioavailabilities Underpredicted?




### **Expected Effects of UGT\* and hP-gp Activity on Rat PK**



\*Based on expression levels of rat orthologs of human UGTs and hUGT substrate classifications


# **Rat Bioavailability: Data Set 2**

- Data taken from drug design and development papers published in the *Journal of Medicinal Chemistry* between 2006 and 2012 that report oral bioavailability in rats for one or more analogs
  - rat bioavailabilities for 51 compounds with many different targets
  - 1-11 examples from 17 papers






### Effect of Being a Possible P-gp Substrate\* on Predicted Rat PK




\*Based on confidence in human P-gp substrate classification

# Effect of Being a Possible UGT Substrate\* on Predicted Rat PK



\*Based on expression levels of rat orthologs of human UGTs and hUGT substrate classifications


# **Predicting Fa and Fb for Pesticides**



RD Clark. Predicting mammalian metabolism and toxicity of pesticides *in silico*. *Pest Management Science*, published online 15 May 2018; DOI 10.1002/ps.4935.



# **Comparing Predictions for Different Species**




RD Clark. Predicting mammalian metabolism and toxicity of pesticides *in silico*. *Pest Management Science*, published online 15 May 2018; DOI 10.1002/ps.4935.



# The Streamlined System Output is Similar to Full Simulation\*

125 compounds from Zhao et al., J. Pharm. Sci. 2001, 90:749



\*GastroPlus run using a compartmental model with ACAT absorption vs HTPK in ADMET Predictor.

St Simulations Plus SCIENCE + SOFTWARE = SUCCESS

# Conclusions

- The high-throughput implementation of PBPK simulation in ADMET Predictor yields results in good agreement with analogous analyses in GastroPlus.
- HTPK simulations run using purely *in silico* property estimates are in reasonable but imperfect agreement with experimental results in humans and rats.
- Most experimental bioavailabilities for lead-type compounds in rat fall near or below the predicted fraction absorbed, which suggests that %Fa estimates are accurate.
- Increasing the accuracy of bioavailability estimation using *in silico* property estimates will require quantitative accounting for transporters and non-CYP metabolism.
- Measuring absorption and bioavailability is hard, as is modeling them. Validating the models designed to estimate them may be even harder.



# My thanks to:

- Pankaj Daga & Robert Fraczkiewicz
- David Miller
- Eric Martin & Ben Madej (Novartis)
- Michael Lawless
- Mike Bolger
- Viera Lukacova
- John DiBella
- Karen Webster

...and to you: Hvala lepa!

bob@simulations-plus.com



©Simulations Plus, Inc., 2018 All rights reserved